Update 2/27/21: The FDA has approved J&J’s Covid-19 vaccine for emergency use
Feb. 24, 2021– the Food & Drug Administration (FDA) has indicated Johnson & Johnson’s COVID-19 vaccine has met requirements for emergency use authorization (EUA). The report from staff will be used to brief the Vaccines & Related Biological Products Advisory Committee meeting, Feb. 26, to review Johnson & Johnson’s application for EUA of the single shot vaccine.
From CNN website: In a briefing document, the FDA said that it has reviewed the data for the vaccine and has determined that it is “consistent with the recommendations set forth in FDA’s guidance Emergency Use Authorization for Vaccines to Prevent COVID-19.”
The level of protection varied in different regions worldwide, with 72% effectiveness in the US, 66% overall, at preventing moderate to severe COVID-19, 28 days after vaccination. according to a Feb. 4 Johnson & Johnson report to the FDA.
CNBC website said: “Vaccine effectiveness was similar across age, race and people with comorbidities, the FDA staff said. However, the effectiveness appeared to be lower in people who were 60 years or older who also had comorbidities, like diabetes or heart disease, the agency said, adding the efficacy rate was 42.3% about a month after getting the shot.”
LDA NOTE: Different news sources may contain slightly different information. Currently at this printing, the FDA website does not have the announcement.